PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma to Present on Creating Market Opportunities At 2011 BIO Business Forum - Panel session and presentation will explore half-life extension technologies designed to overcome challenges associated with the therapeutic use of peptides and proteins - Novozymes.com
Novozymes Biopharma to Present on Creating Market Opportunities At 2011 BIO Business Forum

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2011/06/23 - Panel session and presentation will explore half-life extension technologies designed to overcome challenges associated with the therapeutic use of peptides and proteins - Novozymes.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, today announced that it will be hosting a panel session within the manufacturing of biologics and drugs session track at the BIO Business Forum, during the 2011 BIO International Convention in Washington D.C, June 27-30. Svend Licht, senior director, Novozymes Biopharma will be moderating the session entitled 'Patient Compliance and market opportunities - the need for half-life extension' on Tuesday 28th June at 8.30am in room 156 AB, along with guest speakers from the world's leading drug development companies, including Pfizer, Sanofi, Teva Pharmaceuticals and Roche. The panel has been identified as leaders in their respective fields who use differing means of improving pharmacokinetics of biological drugs to offer enhanced benefits in the clinic.

To increase market share for a given drug, pharmaceutical companies must consider healthcare costs, user acceptance and patient compliance. The parenteral delivery of therapeutic proteins and peptides is often associated with poor stability, immunogenicity or lack of efficacy due to short protein half-life or poor bioavailability. As a consequence, there is an identified need for solutions that extend the plasma half-life of drugs when delivered systematically. The panel session will address such challenges and describe how companies can design and manufacture improved drugs with better pharmacokinetic profiles.

A presentation by Dr. Dave Mead, business development director at Novozymes Biopharma will also take place on Tuesday 28th June at 2.00pm in the Georgetown presentation room. The presentation will explore the challenges associated with poor pharmacokinetic profiles and introduce innovative new technologies that offer the potential to tailor drug half-life, thereby enhancing effectiveness, while improving patient quality of life.

The presentation will also highlight Novozymes' innovative research into albumin and its receptor that saves it from the normal degradative pathway experienced by other plasma proteins. These advances in the production of albumin fusions have provided the basis for Novozymes' next generation Albufuse®Flex technology built on the company's original Albufuse platform, which enables the half-life of a drug to be tailored.

Dr. Dave Mead comments,"The BIO International Convention is the largest global event for the biotechnology industry and speakers at the event represent companies that are at the leading edge of their respective areas.
We are delighted to have been selected to speak at the BIO Business Forum and look forward to sharing insight into Novozymes' recent innovations which pave the way for flexibility and efficiency to support manufacturers in developing novel drugs."

About Novozymes

Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma to Present on Creating Market Opportunities At 2011 BIO Business Forum

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sally Vernon - Novozymes.com 
+44 115 955 3355 SYKE[.]novozymes.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)